Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia

European Respiratory Journal

Volumn 24, Issue 4, 2004, Pages 644-648

  Wasserfallen, Jean Blaise ^a   Erard, V ^a   Cometta, A ^b   Calandra, T ^a   Lamy, O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Centre Hospitalier Yverdon Chamblon   (Switzerland)

Author keywords

Community acquired pneumonia; Cost effectiveness; Economics; Fluoroquinolones; Oral therapy

Indexed keywords

CEFTRIAXONE; CLARITHROMYCIN; LEVOFLOXACIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; HEALTH SERVICE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; MULTICENTER STUDY; PATIENT TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REHABILITATION CENTER; WORK DISABILITY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 6444239085     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00143303     Document Type: Article

References (20)

1. Marrie JF, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000; 283: 749-755.
2. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275: 134-141.
3. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534.
4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837.
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997; 336: 243-250.
6. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
7. Ramirez JA. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia. Ann Pharmacother 1998; 32: S22-S26.
8. Rhew DC, Hackner D, Henderson L, Gray Ellrodt A, Weingarten SR. The clinical benefit of in-hospital observation in " low-risk" pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998; 113: 142-146.
9. Martin SJ, Sahloff EG, Close SJ. Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections. Expert Opin Pharmacother 2002; 3: 1251-1266.
10. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001; 119: 1439-1448.
11. Drummond ME, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./p.o. moxifloxacin therapy compared to i.v./p.o. co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003; 124: 526-535.
12. Erard V, Lamy O, Bochud PY, Bille J, Cometta A, Calandra T. Full course oral levofloxacin for the treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2004; 23: 82-88.
13. Tilquin C. Un cadre conceptuel et méthodologique pour les classifications de malades selon leurs besoins en soins infirmiers [Conceptual and methodological framework for patients' classification according to their needs in nursing care]. In: Coblentz AM, Walter JR, eds. Systems science in health care. London, Taylor & Francis, 1977; pp. 289-296.
14. Compendium Suisse des Médicaments. Morant J, Ruppanner H, eds. 21st Edn. Basel, Documed SA, 2000. www.documed.ch. Date last accessed: July 8 2004. Date last updated: July 8 2004.
15. International Standard Classification of Occupations (ISCO-88 COM). Warwick Institute for Employment Research. www2.warwick.ac.uk/fac/soc/ier/research/isco88/english. Date last accessed: July 8 2004. Date last updated: February 18 2004.
16. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109: 378-385.
17. Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and cost in more than 2000 patients with community-acquired pneumonia. Am J Med 1998; 104: 17-27.
18. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278: 32-39.
19. Halm EA, Atlas SJ, Borowsky LH, et al. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. Arch Intern Med 2000; 160: 98-104.
20. Whittle J, Lin CJ, Lave JR, et al. Relationship of provider characteristics to outcomes, process, and costs of care for community-acquired pneumonia. Med Care 1998; 36: 977-987.